Strata Mental Health Wins Compass Pathways Grant for COMP360 Provider Training

Lobe Sciences Ltd. announced that Chairman and Chief Executive Officer Dr. Frederick D. Sancilio will present clinical and preclinical data for Conjugated Psilocin, or L-130, at the 9th Neuropsychiatric Drug Development Summit, held September 15-17, 2026 in Boston, Massachusetts. Dr. Sancilio's presentation, titled "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm," is scheduled for 11:00 a.m. ET on Wednesday, September 16 in the summit's preclinical and translational track. The presentation sets out the case for patented L-130 as a candidate suited to daily outpatient dosing rather than the supervised in-clinic administration that psychedelic-class candidates typically require, covering the compound's formulation characteristics as a patented salt of psilocin, the active moiety itself rather than a prodrug, together with first-in-human results in ten subjects showing consistent oral pharmacokinetics and preclinical findings on daily low-dose administration. Lobe will also exhibit throughout the three-day summit, which brings together senior discovery, translational, clinical, regulatory and business development leaders from large pharmaceutical companies, biotechnology companies and investors active in neuropsychiatric drug development. L-130 is initially being developed for cluster headache, with co-development programs underway for PTSD, substance use disorder, generalized anxiety disorder and other neuropsychiatric disorders, while the company is also advancing S-100 for sickle cell disease, with Phase 3 clinical development anticipated to commence in mid-2027.